Real‑time stock data, professional analysis, and smart portfolio tools. One platform for all your investing needs.

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis – Slideshow

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis – Slideshow#Spyre #Therapeutics #SYRE #Discusses #SPY001 #Part #Induction #Topline #Results #SKYLINE #Trial #ModeratetoSevere #Ulcerative #Colitis #Slideshow

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis – Slideshow

相关文章

Jamie Dimon strikes cautious tone as JP Morgan profit beats target

Roblox: 2025 Was A Good Year, But Bans In Several Countries Weigh On The Outlook

Darts drives Matchroom profit as promoter warns of gambling law impact